Stock Analysis
AstraZeneca (LON:AZN) First Quarter 2024 Results
Key Financial Results
- Revenue: US$12.7b (up 17% from 1Q 2023).
- Net income: US$2.18b (up 21% from 1Q 2023).
- Profit margin: 17% (in line with 1Q 2023).
- EPS: US$1.41 (up from US$1.16 in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
AstraZeneca Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 7.1%. Earnings per share (EPS) also surpassed analyst estimates by 6.3%.
Looking ahead, revenue is forecast to grow 6.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in the United Kingdom.
Performance of the British Pharmaceuticals industry.
The company's shares are up 10% from a week ago.
Risk Analysis
It is worth noting though that we have found 2 warning signs for AstraZeneca that you need to take into consideration.
Valuation is complex, but we're helping make it simple.
Find out whether AstraZeneca is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About LSE:AZN
AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Good value with reasonable growth potential and pays a dividend.